X

News

BeiGene News

See all News

  • July 9, 2021
    BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

    BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

    Read More
  • July 7, 2021
    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

    Read More
  • June 23, 2021
    China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

    China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

    Read More
  • June 18, 2021
    BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

    BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

    Read More
  • June 17, 2021
    BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

    BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

    Read More
  • June 11, 2021
    BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

    BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

    Read More
  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160    Listings
  • 8Internally Developed
    Clinical Candidates
  • 8Marketed
    Products
    in China
  • 1Approved
    Product
    in the U.S.
  • ~6,000Global Team
story
 
BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

2010

  • BeiGene was founded as a research and development company
BeiGene R&D Center

2011

  • Established the first R&D center in Beijing
  • Initiated PARP and RAF discovery programs
Immuno-oncology Therapies

2012

  • Initiated PD-1 and BTK discovery programs 
Clinical development in Australia

2013

  • Began clinical development of lifirafenib in Australia
Clinical Researcher

2014

  • Began clinical development of pamiparib and zanubrutinib in Australia
BeiGene opens first US office

2015

  • Began clinical development in China
  • Expanded into the U.S. with the first office established in Cambridge, MA
First China biotech to go public on the Nasdaq

2016

  • Became the first biotech to go public on Nasdaq in 2016 after a months-long offering freeze with a $182 million IPO
Collaboration with Celgene

2017

  • Initiated the first global Phase 3 registrational trial of zanubrutinib
  • Entered a global strategic immuno-oncology collaboration with Celgene (now Bristol Myers Squibb) on tislelizumab
  • Transformed into a commercial-stage company by absorbing Celgene’s commercial operation in China
  • Completed construction of the Suzhou multi-functional manufacturing facility
BeiGene expands global operations

2018

  • Completed dual primary listing on Hong Kong Stock Exchange with a $902 million IPO
  • Expanded into Europe with opening of the Basel office
  • Secured national reimbursement in China for both Revlimid® and Vidaza®*
Established research institute

2019

  • Received the first FDA approval for BRUKINSA® (zanubrutinib)
  • Received the first approval for tislelizumab in China
  • Entered a global strategic oncology collaboration with Amgen
  • Completed the first plant of the Guangzhou biologics manufacturing facility
  • Established BeiGene Suzhou Research Institute
Clinical development

2020

  • Received the first approvals for BRUKINSA® in China
  • Received the second approval for tislelizumab in China
  • Completed a registered direct offering of approx. $2.07 billion
  • Secured national reimbursement in China for tislelizumab, BRUKINSA®, and XGEVA®**
  • Established the Shanghai R&D center
third approval for tislelizumab

2021

  • Entered a global strategic collaboration with Novartis
  • Received the third approval for tislelizumab in China
  • Received the first approval for pamiparib in China

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeagen_LogoAmbrx LogoMirati LogoMEI logoAmgen logoEUSA LogoAssembly Bio LogohutchmedBio-Thera LogoSinglomics LogostandtxBITT LogoNovartisShoreline

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers